Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - A pooled meta-analysis of randomized placebo-controlled clinical trials

International Journal of Cardiology

Volumn 141, Issue 2, 2010, Pages 157-166

  Saha, Sandeep A ^a,b   Arora, Rohit R ^c  

^a SACRED HEART MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c The Chicago Medical College   (United States)

Author keywords

Cardiovascular disease; Clinical trials; Diabetes mellitus; Fibrates; Meta analysis; Prevention

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; ETOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PLACEBO;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; DRUG EFFECT; DRUG USE; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; HUMANS; LIPIDS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 77952236941     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.211     Document Type: Article

References (43)

1. No authors listed. Complications of Diabetes in the United States. Available on the American Diabetes Association website (URL: http://www.diabetes.org/diabetes-statistics/complications.jsp). Accessed November 26, 2007.
2. Schramm T.K., Gislason G.H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk. Circulation 117 (2008) 1945-1954
3. Shepherd J. Dyslipidaemia in diabetic patients: time for a rethink. Diabetes Obes Metab 9 (2007) 609-616
4. Rizzo M., Rini G.B., and Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 115 (2007) 477-482
5. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
6. Sacks F.M., and for the Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
7. Jacobson T.A., Miller M., and Schaefer E.J. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther 29 (2007) 763-777
8. de Gennes J.L., Maunand B., Salmon D., et al. Results of atromid or CPIB treatment with and without androsterone in hyperlipemia (110 therapeutic trials in 2 years). Bull Mem Soc Med Hop Paris 116 (1965) 759-784
9. Birjmohun R.S., Hutten B.A., Kastelein J.J.P., et al. Efficacy and safety of high-density lipoprotein cholesterol increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
10. Brown W.V. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am J Cardiol 99 6A (2007) 19C-21C
11. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
12. Lock E.A., Mitchell A.M., and Elcombe C.R. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol 29 (1989) 145-163
13. Zandbergen F., and Plutzky J. PPARα in atherosclerosis and inflammation. Biochim Biophys Acta 1771 (2007) 972-982
14. Duval C., Müller M., and Kersten S. PPARα and dyslipidemia. Biochim Biophys Acta 1771 (2007) 961-971
15. Lefebvre P., Chinetti G., Fruchart J.C., et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116 (2006) 571-580
16. Zambon A., Gervois P., Pauletto P., et al. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators - clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 (2006) 977-986
17. Marx N., Duez H., Fruchart J.C., et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 9 (2004) 1168-1178
18. Corti R., Osende J., Hutter R., et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 190 1 (2007) 106-113
19. Duez H., Chao Y.S., Hernandez M., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277 50 (2002) 48051-48057
20. Frick M.H., Syvanne M., Nieminen M.S., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-C cholesterol. Circulation 96 (1997) 2137-2143
21. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
22. Diabetes Atherosclerosis Intervention Study (DAIS) investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357 (2001) 905-910
23. May H.T., Anderson J.L., Pearson R.R., et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 101 4 (2008) 486-489
24. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
25. Verhagen A.P., de Vet H.C.W., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51 12 (1998) 1235-1241
26. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 20 (1987) 1237-1245
27. Koskinen P., Mänttäri M., Manninen V., et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 7 (1992) 820-825
28. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
29. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans' Affairs High-density lipoprotein Intervention Trial (VA-HIT). Arch Int Med 162 (2002) 2597-2604
30. The BIP Study Group. Secondary prevention by raising HDL-C cholesterol and reducing triglycerides in patients with coronary artery disease - the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
31. Tenenbaum A., Motro M., Fisman E.Z., et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Int Med 165 (2005) 1154-1160
32. The FIELD study investigators. Effects on long-term fenofibrate therapy on cardiovascular events in 9795 in the people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366 (2005) 1849-1861
33. Elkeles R.S., Diamond J.R., Poulter C., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21 4 (1998) 641-648
34. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 4 (1959) 719-748
35. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
36. Meade T., Zuhrie R., Cook C., et al. Bezafibrate in men with lower extremity arterial disease: randomized controlled trial. BMJ 325 (2002) 1139-1143
37. Ruotolo G., Ericsson C.G., Tettamanti C., et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the bezafibrate coronary atherosclerosis intervention trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
38. Allemann S., Diem P., Egger M., et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Curr Med Res Opin 22 3 (2006) 617-623
39. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
40. American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care 31 suppl 1 (2008) S12-S54
41. No authors listed. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available online at http://www.accordtrial.org/public/index.cfm. Accessed April 1, 2008.
42. Carter A.O., Griffin G.H., and Carter T.P. A survey identified publication bias in the secondary literature. J Clin Epidemiol 59 3 (2006 Mar) 241-245
43. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150